Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients

Highlights • The risk of recurrence in ovarian cancer (OC) represents a common entity. • The role of tyrosine-kinases inhibitors (TKI) in recurrent OC needs to be clarified. • This is the largest reported analysis of published data. • This analysis suggests that TKI could be considered a valid optio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer treatment reviews 2016-01, Vol.42, p.41-46
Hauptverfasser:	Marchetti, C, Palaia, I, De Felice, F, Musella, A, Donfracesco, C, Vertechy, L, Romito, A, Piacenti, I, Musio, D, Muzii, L, Tombolini, V, Benedetti Panici, P
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Carcinoma - drug therapy Carcinoma - enzymology Carcinoma - secondary Clinical Trials, Phase II as Topic Drug Resistance, Neoplasm - drug effects Female Gynecologic Hematology, Oncology and Palliative Medicine Humans Molecular Targeted Therapy Multicenter Studies as Topic Neoplasm Proteins - antagonists & inhibitors Organoplatinum Compounds - pharmacology Organoplatinum Compounds - therapeutic use Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - enzymology Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - secondary Platinum resistant Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Randomized Controlled Trials as Topic Recurrence Treatment Outcome Tyrosine-kinases inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • The risk of recurrence in ovarian cancer (OC) represents a common entity. • The role of tyrosine-kinases inhibitors (TKI) in recurrent OC needs to be clarified. • This is the largest reported analysis of published data. • This analysis suggests that TKI could be considered a valid option in recurrent OC.
ISSN:	0305-7372 1532-1967
DOI:	10.1016/j.ctrv.2015.10.011